Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
K.ChenL
This ongoing surveillance system allows the FDA to identify potential safety signals that may not have been apparent in pre-approval trials
Following our data for CT-388, this is the second positive readout in less than three months from our growing metabolic pipeline, which includes both oral and injectable options to address patients' needs across a spectrum of related diseases." CT-996 was well tolerated, with mostly mild or moderate gastrointestinal-related adverse events, consistent with the safety profile of the incretin drug class
Community members most commonly report improved energy levels and reduced general fatigue as early indicators, typically within the first 1-2 weeks
Although no cases have been reported in humans, some studies have reported a possible association between GLP-1 agonist use and increased risk of thyroid cancer
US$ 23.99
US$ 21.94
US$ 24.89
US$ 23.23
